| Jun 20 |
Recent 5.2% pullback isn't enough to hurt long-term MannKind (NASDAQ:MNKD) shareholders, they're still up 327% over 5 years
|
| Jun 5 |
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
|
| May 29 |
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
|
| May 29 |
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
|
